Checkpoint Therapeutics, Inc., clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

Checkpoint Therapeutics, Inc.

Checkpoint Therapeutics is a company that develops novel treatments for cancer patients. The company aims to lower risk and accelerate the development and commercialization of oncology drugs.

Checkpoint Therapeutics

Checkpoint Therapeutics is revolutionizing the way novel treatments for cancer patients are developed. As a fast-follower, our streamlined approach lowers risk and accelerates the development and commercialization of oncology drugs, ensuring more patients, payors and providers benefit from effective and more affordable treatment options.

Checkpoint Therapeutics Inc

Checkpoint Therapeutics today announced that the U.S. Food and Drug Administration has accepted for review Checkpoint’s resubmission of its Biologics License Application for cosibelimab. The resubmission has been accepted as a complete response to the FDA’s December 2023 complete response letter and the FDA has set a Prescription Drug User Fee Act goal date of December 28, 2024. Read the full release: https://lnkd.in/g_aJ5-N4

Self-care looks different for everyone. On #InternationalSelfCareDay, Checkpoint Therapeutics encourages prioritizing personal care and sun protection. Consider implementing these tips in your daily routine:

Avoid excessive sun exposure or bed tanning, as these activities can increase your risk of skin cancer. Always wear SPF skin protection when going outside for extended periods of time.

Remember to treat your lips. Skin on the lips is sensitive and can be prone to sunburn if overexposed, so keep SPF lip balm with you.

Check your skin regularly and contact your doctor with any concerns.

For more information and additional resources, visit: 
https://lnkd.in/e34uMm7

Checkpoint Therapeutics had the honor of attending the American Cancer Society's annual Red, White & Blue Party this year! This remarkable event gathers dedicated professionals and philanthropic leaders, all driven by a shared commitment to support the mission of the American Cancer Society.

As a proud sponsor, Checkpoint believes in the power of community and the importance of giving back. We are immensely grateful to The American Cancer Society for their efforts in enhancing the lives of those affected by cancer.

Today, Checkpoint Therapeutics and GC Cell announced a collaboration to explore the combined therapeutic potential of cosibelimab, Checkpoint’s anti-PD-L1 antibody with dual mechanism of action, with GC Cell’s Immuncell-LC, an innovative autologous Cytokine Induced Killer (CIK) T cell therapy composed of cytotoxic T lymphocytes and natural killer T cells. Read more about the partnership: https://lnkd.in/edDNAnMq

Today, Checkpoint Therapeutics announced it has completed the resubmission of its Biologics License Application to the U.S. Food and Drug Administration for cosibelimab, its anti-programmed death ligand-1 (PD-L1) antibody, as a potential new treatment for patients with metastatic or locally advanced cutaneous squamous cell carcinoma who are not candidates for curative surgery or curative radiation. Read the full release: https://lnkd.in/eG5CY9nX

Checkpoint recently attended the American Cancer Society’s North Carolina Discovery Ball, an annual event uniting professional and philanthropic leaders in the fight against cancer. As a proud sponsor, Checkpoint is grateful for the American Cancer Society and its long history of unwavering commitment to cancer research, education and advocacy.

NASDAQ:CKPT

Checkpoint Therapeutics

Last Close

2.34

30/08 20:00

Market Cap

82.24M

Beta: 1.44

Volume Today

155.05K

Avg: 295.57K

PE Ratio

−0.73

PFCF: −0.75

Financials Not Available